Affiliation:
1. Department of Orthopedic, The Second People’s Hospital of Yibin, Yibin, China
2. Department of Nephrology, The Second People’s Hospital of Yibin, Yibin, China.
Abstract
Background:
Previous studies explored the prognostic value of pretreatment platelet count, fibrinogen, and d-dimer level in patients with several types of cancer, however, a comprehensive conclusion has not been reached in osteosarcoma patients.
Methods:
PubMed, Web of Science, Embase, and CNKI databases were systematically searched for eligible studies up to May 09, 2023, and pooled hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) were calculated to assess the prognostic impact of these indicators in osteosarcoma patients.
Results:
Twelve studies from China consisting of 1682 patients were finally included. Our findings revealed that an elevated level of pretreatment platelet or d-dimer was associated with a worse outcome of overall survival (platelet: HR = 1.63, 95% CI: 1.18–2.26, P = .003; d-dimer: HR = 2.29, 95% CI: 1.58–3.31, P < .001).
Conclusion:
Based on current evidence, pretreatment platelet count and d-dimer level could be good prognostic biomarkers for Chinese osteosarcoma patients. However, future validation is also needed.
Publisher
Ovid Technologies (Wolters Kluwer Health)